| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | — | 0.0 |
| Profit before tax | -31.6 | -19.0 |
| Net income | -31.6 | -19.0 |
| EPS (diluted, $ a share) | $-0.15 | $-0.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ALT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Altimmune, Inc.: key numbers
- Share price
- $1.56Close, Nov 16
- Market cap
- $304M
- Shares outstanding
- 194.59MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Altimmune, Inc.
All →Altimmune CFO Gregory L. Weaver Buys $16.2K of Stock
Gregory L. Weaver, CFO, bought 10,000 shares of Altimmune, Inc. at $1.62 a share, worth $16.2K in total on Nov 13, 2026. Shares held after the trade: 73,005 (+15.9%).
- Value
- $16.2K
- Shares
- 10,000
- Price
- $1.62
- Role
- CFO
- Holding change
- +15.9%
- Trade date
- Nov 13, 2026
Altimmune Director Wayne Pisano Buys $16.4K of Stock
Wayne Pisano, Director, bought 10,000 shares of Altimmune, Inc. at $1.64 a share, worth $16.4K in total on Nov 13, 2026. Shares held after the trade: 58,800 (+20.5%).
- Value
- $16.4K
- Shares
- 10,000
- Price
- $1.64
- Role
- Director
- Holding change
- +20.5%
- Trade date
- Nov 13, 2026
Altimmune President and CEO Jerome Benedict Durso Buys $49.7K of Stock
Jerome Benedict Durso, President and CEO, bought 30,700 shares of Altimmune, Inc. at $1.62 a share, worth $49.7K in total on Nov 13, 2026. Shares held after the trade: 93,200 (+49.1%).
- Value
- $49.7K
- Shares
- 30,700
- Price
- $1.62
- Role
- President and CEO
- Holding change
- +49.1%
- Trade date
- Nov 13, 2026
Altimmune Financial Results
Altimmune reported third quarter 2026 financial results and provided a business update on its pemvidutide clinical programs. The company ended the quarter with $480 million in cash and is progressing its Phase 3 PERFORMA trial in MASH and preparing for an End-of-Phase 2 meeting with the FDA for its AUD program in December 2026.
“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide. Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community.”
Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune
“In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program. Following the recent AASLD meeting, our conviction in pemvidutide’s potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases.”
Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune
Altimmune $10M Debt Financing with Hercules Capital, Inc.
Altimmune, Inc. has drawn down $10.0 million (Tranche Three) from its existing $125.0 million Loan and Security Agreement with Hercules Capital, Inc. following the achievement of specific clinical and financial milestones. The draw-down extends the interest-only period and amortization date to June 1, 2028, and requires the company to maintain a minimum cash balance equal to 60% of the outstanding principal.
- Value
- $10M
- Counterparty
- Hercules Capital, Inc.
- Term
- through June 1, 2028
Altimmune Leadership Change
Altimmune appointed Peter Greenleaf and Alex Howarth to its Board of Directors effective November 2, 2026, increasing the board size to eleven. As part of a planned transition, directors John M. Gill, Mitchel Sayare, and Klaus O. Schafer will retire at the 2027 Annual Meeting. The new directors will receive an annual cash retainer of $40,000 and initial stock options for 160,000 shares each.